Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2025-06-02 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
HREC Approval for Redesigned IRX-211 Phase 2 Trial 2 pages 163.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 3 June 2025 regarding Human Research Ethics Committee (HREC) approval for a redesigned clinical trial (IRX-211) by InhaleRx Limited. It discusses trial design changes, expanded scope, and manufacturing arrangements. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (3879 characters) and serves as a corporate update on clinical trial progress and regulatory approval rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a regulatory filing in the sense of officer certifications or compliance documents, but rather a corporate announcement about clinical trial progress and approvals. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2025-06-02 English
2025 AGM Slides 29 pages 1.3MB
AGM Information Classification · 100% confidence The document is a detailed record of an Annual General Meeting (AGM) held on 29 May 2025. It includes the agenda, resolutions proposed and voted on by shareholders, proxy vote counts, and formal meeting closure. The content focuses on shareholder voting on various resolutions including director elections, remuneration report adoption, and equity issuance approvals. It also contains a shareholder update on business activities and financial statements for the year ended 31 December 2024. The presence of detailed voting results and meeting procedures is characteristic of AGM materials. There is no indication that this is a full annual report or financial statement document itself, but rather the materials and results from the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2025-05-28 English
Results of 2025 AGM 2 pages 279.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 29 May 2025, titled 'RESULTS OF ANNUAL GENERAL MEETING'. It details the voting results of twelve resolutions put to shareholders at the Annual General Meeting (AGM) of InhaleRx Ltd. The content includes proxy votes, poll results, and whether each resolution was carried or not. There is no financial data or report content, only the official voting results from the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is about 5200 characters, which is sufficient to contain detailed voting results but not a full report. Therefore, the correct classification is DVA with high confidence.
2025-05-28 English
Change of Director's Interest Notice - Sean Williams 3 pages 308.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares and options held before and after the change, the nature of the change, and other related information. This type of document is a formal notification of personal share transactions by a company director, commonly known as a director's dealing report. It does not contain financial performance data, management discussion, or other report content. The document length is 4583 characters, which is consistent with a detailed director's dealing notice. Therefore, the appropriate classification is 'DIRS' (Director's Dealing).
2025-05-14 English
Notification of cessation of securities - IRX 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry) of certain securities (options) for Inhalerx Limited. It includes specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor an earnings release or audit report. It is also not a report publication announcement or a certification. The document is a regulatory announcement about securities cessation, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit more specific categories like share issue or capital change (SHA) or director dealings (DIRS). The document is about cessation of securities, which is a regulatory announcement but not a new share issue or capital change per se. Therefore, the best classification is Regulatory Filings (RNS). Confidence is high given the clear nature of the document and its content.
2025-05-12 English
2025 AGM Notice of Meeting 30 pages 537.7KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed agenda items typical for an AGM notice, such as the time, date, place (virtual meeting), and the business of the meeting. It lists resolutions for adoption of the remuneration report, election and re-election of directors, approval of equity securities issuance, and other shareholder voting matters. It also includes voting exclusion statements and proxy voting instructions. The document does not contain actual financial statements or detailed financial data but refers to the annual financial report to be received and considered at the meeting. This is a classic example of an AGM notice document, which is distinct from the actual annual report or other filings. Therefore, the correct classification is AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is a full notice rather than a brief announcement or proxy statement.
2025-04-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.